Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1609 - The retrospective analysis of nephrotoxicity for cisplatin dose of CRT compared 100 mg/m2 to 80 mg/m2 for head and neck cancer (HNC) patients

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Tomoyo Oguri

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

T. Oguri1, K. Nakano1, N. Fukuda1, K. Kawaguchi1, T. Urasaki1, M. Nishizawa1, M. Yunokawa1, M. Ono1, S. Taira1, J. Tomomatsu1, T. Toshiyasu2, H. Mitani3, S. Takahashi4

Author affiliations

  • 1 Department Of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 135-8550 - Tokyo/JP
  • 2 Department Of Radiation oncology,, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 135-8550 - Tokyo/JP
  • 3 Head And Neck Surgery, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 1358550 - Tokyo/JP
  • 4 Department Of Medical Oncology, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
More

Resources

Abstract 1609

Background

Concurrent chemoradiotherapy (CRT) with single agent cisplatin for patients with head and neck cancers (HNC) have been used as the standard treatment for a long time. Although recommended dose of cisplatin is 100mg/m2, we sometimes reduced cisplatin dose to 80mg/m2 depends on general condition in real world setting. It remains unclear whether the efficacy and the safety, especially in nephrotoxicity, for CRT of HNC patients with cisplatin dose 100mg/m2 or 80mg/m2 are different.

Methods

We reviewed medical records of NHC patients who received CRT in our institute retrospectively. The primary objectives of this study were to evaluate the nephrotoxicity and the rate of patients treated with cumulative dose of cisplatin 200mg/m2 or more.

Results

During January 2014 to October 2017, 261 HNC patients who received CRT were treated. The starting dose of cisplatin were 80mg/m2 in 118 patients vs 100mg/m2 in 143 patients, respectively. There were more patients over 70 years who received cisplatin in 80mg/m2 than 100mg/m2 (27.1% vs 4.2%, p < 0.001). The mean Creatinine Clearance (Ccr) obtained using the Cockcroft-Gaut at baseline was significantly lower in 80mg/m2 than 100mg/m2 (87.82 vs 97.28, p = 0.0022). There were no significantly differences in patient’s other characteristics as follows gender, performance states, pathology. The incidence of Grade 2 or higher elevation in creatinine was 2 (1.7%) in 80mg/m2 group and 4 (2.8%) in 100mg/m2 group, respectively (p = 0.554). The rate of change in CCR showed no difference between both groups (-5.73% in 80mg/m2 vs -7.63% in 100mg/m2, p = 0.2927), either. The rate of cumulative dose of cisplatin ≧200mg/m2 was significantly higher in 100mg/m2 than 80mg/m2 (97.2% vs 72.0%, p < 0.001). 2-year PFS rate was not significantly different between 80 mg/m2and 100 mg/m2 in oropharynx (89.3% vs 88.2%, p = 0.7760) and in hypopharynx/ larynx (70.28% vs 80.92%, p = 0.4740), respectively.

Conclusions

Cisplatin dose of CRT for HNC patients in 100mg/m2was feasible without increasing the nephrotoxicity and the rate of cumulative dose of cisplatin ≧ 200mg/m2was higher compared to 80mg/m2.

Clinical trial identification

The study protocol was approved by the local institutional review board (approval no. 2017-1197) and conducted in accordance with the provisions of the Declaration of Helsinki and local regulations.

Legal entity responsible for the study

Tomoyo Oguri.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.